Rock Springs Capital Management LP Q2 2023 Filing
Filed August 14, 2023
Portfolio Value
$4.2T
Holdings
123
Report Date
Q2 2023
Filing Type
13F-HR
All Holdings (123 positions)
| Stock | Value |
|---|---|
TVTX 2.5 09/15/25TRAVERE THERAPEUTICS INC | $2.9M |
BDTXBLACK DIAMOND THERAPEUTICS I | $2.8M |
ADAPYADAPTIMMUNE THERAPEUTICS PLC | $2.6M |
FULCFULCRUM THERAPEUTICS INC | $2.4M |
—KINNATE BIOPHARMA INC | $2.3M |
IMGNEURIMMUNOGEN INC | $2.1M |
NVTA1EURINVITAE CORP | $1.9M |
EPIEURESSA PHARMA INC | $1.8M |
AGLEUSDAEGLEA BIOTHERAPEUTICS INC | $1.5M |
CGENCOMPUGEN LTD | $1.5M |
—GAMIDA CELL LTD | $1.4M |
GOSSGOSSAMER BIO INC | $1.3M |
NBIX 2.25 05/15/24NEUROCRINE BIOSCIENCES INC | $1.3M |
—VINCERX PHARMA INC | $1.2M |
APLTAPPLIED THERAPEUTICS INC | $999K |
SPROSPERO THERAPEUTICS INC | $971K |
ALTALTIMMUNE INC | $788K |
NKTXNKARTA INC | $726K |
OVASUSDTEMPEST THERAPEUTICS INC | $681K |
NVRO 2.75 04/01/25NEVRO CORP | $462K |
BCELATRECA INC | $355K |
TLPHACELRX PHARMACEUTICALS INC | $351K |
NUVB/WSNUVATION BIO INC | $22K |
PreviousPage 2 of 2